Clinical Translation of Anti-PECAM-1 Monoclonal Antibody as an

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N43CO201000116
Agency Tracking Number: N43CO201000116
Amount: $198,751.00
Phase: Phase I
Program: SBIR
Awards Year: 2010
Solicitation Year: 2010
Solicitation Topic Code: NCI
Solicitation Number: PHS2010-1
Small Business Information
DUNS: 825061778
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Robert Debs
 () -
Business Contact
Phone: (650) 906-5631
Research Institution
Most patients who die from cancer succumb to advanced metastatic cancer. These patients, are mostoften treatment-refractory, and comprise the largest untapped market in cancer. We have developed a uniquely effective anti-PECAM-1 monoclonal antibody (mAb)-based therapy. To our knowledge, this mAb is the only treatment that safely and effectively treats advanced tumor metastases, independent of tumor type. Clinical translation of anti-PECAM-1 mAb therapy could revolutionize the treatment of this now-refractory clinical entity. Therefore, we propose to perform the following pre-clinical studies required to translate antiPECAM- 1 mAb-based therapy into phase I clinical trials in cancer patients.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government